The “Utility” of Highly Toxic Marine-Sourced Compounds

Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study

(2019) Suzanne Trudel et al.   Blood Cancer Journal

Anti-NaPi2b antibody–drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study

(2018) S Banerjee et al.   ANNALS OF ONCOLOGY

40INA novel drug conjugate platform: Redefining the therapeutic window for ADCs

(2018) J Babcook et al.   ANNALS OF ONCOLOGY

Synthesis and evaluation of novel dolastatin 10 derivatives for versatile conjugations

(2018) Shinya Yokosaka et al.   BIOORGANIC & MEDICINAL CHEMISTRY

LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody–Drug Conjugates

(2018) James W. Purcell et al.   CANCER RESEARCH

Phase 1 Trials of anti-ENPP3 antibody drug conjugates in advanced refractory renal cell carcinomas

(2018) John A Thompson et al.   CLINICAL CANCER RESEARCH

Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate

(2018) Andrew C. Phillips et al.   MOLECULAR CANCER THERAPEUTICS

Metabolism of an Oxime-Linked Antibody Drug Conjugate, AGS62P1, and Characterization of Its Identified Metabolite

(2018) Josh T. Snyder et al.   MOLECULAR PHARMACEUTICS

OUP accepted manuscript

(2018)   NEURO-ONCOLOGY

Toward aplyronine payloads for antibody–drug conjugates: total synthesis of aplyronines A and D

(2018) Nika Anžiček et al.   ORGANIC & BIOMOLECULAR CHEMISTRY

MORAb-202, an antibody drug conjugate utilizing humanized anti-human FRa farletuzumab and the microtubule-targeting agent eribulin, has potent anti-tumor activity

(2018) Xin Cheng et al.   MOLECULAR CANCER THERAPEUTICS

Current Status of Marine-Derived Compounds as Warheads in Anti-Tumor Drug Candidates

(2017) David Newman et al.   Marine Drugs

Effect of Attachment Site on Stability of Cleavable Antibody Drug Conjugates

(2015) Magdalena Dorywalska et al.   BIOCONJUGATE CHEMISTRY

A phase 2 study of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in patients (pts) with progressive metastatic castration-resistant prostate cancer (mCRPC) following abiraterone and/or enzalutamide (abi/enz).

(2015) Daniel Peter Petrylak et al.   JOURNAL OF CLINICAL ONCOLOGY

Biological targets and mechanisms of action of natural products from marine cyanobacteria

(2015) Lilibeth A. Salvador-Reyes et al.   NATURAL PRODUCT REPORTS

Site-Dependent Degradation of a Non-Cleavable Auristatin-Based Linker-Payload in Rodent Plasma and Its Effect on ADC Efficacy

(2015) Magdalena Dorywalska et al.   PLoS One

Probody therapeutics for targeting antibodies to diseased tissue

(2014) Krishna R Polu et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

SGN-LIV1A: A Novel Antibody-Drug Conjugate Targeting LIV-1 for the Treatment of Metastatic Breast Cancer

(2014) D. Sussman et al.   MOLECULAR CANCER THERAPEUTICS

Location Matters: Site of Conjugation Modulates Stability and Pharmacokinetics of Antibody Drug Conjugates

(2013) Pavel Strop et al.   CHEMISTRY & BIOLOGY

Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody–drug conjugates

(2012) Diego A. Gianolio et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma

(2012) Peter D Senter et al.   NATURE BIOTECHNOLOGY

Antineoplastic Agents. 592. Highly Effective Cancer Cell Growth Inhibitory Structural Modifications of Dolastatin 10

(2011) George R. Pettit et al.   JOURNAL OF NATURAL PRODUCTS

Tubulin-based antimitotic mechanism of E7974, a novel analogue of the marine sponge natural product hemiasterlin

(2009) G. Kuznetsov et al.   MOLECULAR CANCER THERAPEUTICS